In vivo studies confirmed that PRMT9 suppression inhibited tumor growth, which was associated with decreased expression of RAS, pMek1/2, pErk1/2, and Ki67, alongside enhanced caspase‐3 expression. Here, PRMT9 is linked to neoplasm.